

Docket No.: 112802.1801
Customer No. 21269

PATENT

4B
i.e. alanine, valine, glycine, phenylalanine, arginine or lysine, produces a form of AAT which is more stable. AAT can be represented by the following formula:
MPSSVSWGILLLAGLCCLVPVSLAEDPQGDAQAQKTDTSHHQDHPFNKITPNLAFAFS
LYRQLASTNIFFSPVSIATAFAMLSLGTKADTHDEILEGLNFNLTEIPEAQIHEGFQELLRTL
NQPDSQLQLTTGNGLFLSEGLKLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVE
KGTQGKIVDLVKELDRDITVFALVNYIFFKGKWERPFVVKDTEEEDFHVDQVTTVKVPM
MKRLGMFNIQHCKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLENELTHDITKFLENED
RRSASLHLPKLSITGTYDLKSVLGQLGITKVFNSGADLSGVTEEAPLKLSKAVHKAVLTID
EKGTEAAGAMFLEAIPMSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK (SEQUENCE
ID. NO. 19).

REMARKS

Response to Sequence Listing Request:

Replacement paper and computerized copies of the requested sequence listing, including sequence identification numbers 1-19, as well as a Statement in Support of Sequence Rule Submissions, are being submitted on separate papers concurrently herewith.

Response to Restriction Requirement:

Responsive to the requirement for restriction, Applicant elects Group 13, with traverse. Applicant traverses the restriction requirement for the reasons discussed below.

As set forth in M.P.E.P § 803, there are two criteria for a proper requirement for restriction between patentably distinct inventions: 1) the inventions must be independent or distinct *as claimed*, and 2) there must be a serious burden on the examiner if restriction is required.